| Literature DB >> 35209180 |
Uday M Muddapur1, Sultan Alshehri2, Mohammed M Ghoneim3, Mater H Mahnashi4, Mohammed Abdulrahman Alshahrani5, Aejaz Abdullatif Khan6, S M Shakeel Iqubal6, Amal Bahafi7, Sunil S More8, Ibrahim Ahmed Shaikh9, Basheerahmed Abdulaziz Mannasaheb3, Noordin Othman10,11, Muazzam Sheriff Maqbul12, Mohammad Zaki Ahmad13.
Abstract
Bionanotechnology is a branch of science that has revolutionized modern science and technology. Nanomaterials, especially noble metals, have attracted researchers due to their size and application in different branches of sciences that benefit humanity. Metal nanoparticles can be synthesized using green methods, which are good for the environment, economically viable, and facilitate synthesis. Due to their size and form, gold nanoparticles have become significant. Plant materials are of particular interest in the synthesis and manufacture of theranostic gold nanoparticles (NPs), which have been generated using various materials. On the other hand, chemically produced nanoparticles have several drawbacks in terms of cost, toxicity, and effectiveness. A plant-mediated integration of metallic nanoparticles has been developed in the field of nanotechnology to overcome the drawbacks of traditional synthesis, such as physical and synthetic strategies. Nanomaterials' tunable features make them sophisticated tools in the biomedical platform, especially for developing new diagnostics and therapeutics for malignancy, neurodegenerative, and other chronic disorders. Therefore, this review outlines the theranostic approach, the different plant materials utilized in theranostic applications, and future directions based on current breakthroughs in these fields.Entities:
Keywords: antibacterial; anticancer; antifungal; antioxidant; cytotoxicity; gold
Mesh:
Substances:
Year: 2022 PMID: 35209180 PMCID: PMC8875495 DOI: 10.3390/molecules27041391
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1(A) Proposed synthetic mechanism for plant-mediated synthesis of gold nanoparticles. (B) The advantages of green synthesis over conventional methods.
Figure 2Plant parts extract can be used for the biosynthesis of gold nanoparticles.
Figure 3UV-spectral analysis for gold nanoparticles.
Figure 4FTIR for gold nanoparticles.
Figure 5TEM analysis for gold nanoparticles.
Figure 6XRD analysis for gold nanoparticles.
Figure 7Theranostic applications of AuNPs in medical sciences and applied fields.
Figure 8Principle of MTT assay.
Biological and theranostic applications of gold nanoparticles.
| S. No | Name of the Plant | Activity | Cell Line Used | Shape |
|
|
|---|---|---|---|---|---|---|
| 1 | Nanoparticles with antibacterial activity | |||||
| 1.1 |
| Antibacterial | - | Spherical | 13 | [ |
| 1.2 |
| Antibacterial | - | Spherical | 100 | [ |
| 1.3 |
| Antibacterial | - | Spherical | 16 | [ |
| 1.4 |
| Antibacterial | - | Spherical | 23 | [ |
| 1.5 |
| Antibacterial | - | Rods, triangular, pentagonal, hexagonal | 8–15 | [ |
| 1.6 |
| Antibacterial | - | Spherical, triangular, hexagonal | 10 | [ |
| 1.7 |
| Antibacterial | - | Spherical | 27–30 | [ |
| 1.8 |
| Detections of aflatoxins | - | Sphere | 23–30 | [ |
| 1.9 |
| Antibacterial | - | Spherical | 10–50 | [ |
| 1.10 |
| Antibacterial | - | Triangular, spherical | 40–200 | [ |
| 1.11 |
| Antibacterial | - | Spherical, triangular | 3–9 | [ |
| 1.12 |
| Antibacterial | - | Spherical, triangular | 2–20 | [ |
| 1.13 |
| Bactericidal activity | - | Triangular | 25–40 | [ |
| 1.14 |
| Antibacterial | - | Spherical | 20–48 | [ |
| 1.15 |
| Antibacterial | - | Diverse | 70–90 | [ |
| 1.16 |
| Antibacterial | - | Diverse | 19–56 | [ |
| 1.17 |
| Antibacterial | - | Diverse | 25 | [ |
| 1.18 |
| Antibacterial | - | Spherical | 11 | [ |
| 1.19 |
| Antibacterial | - | Spherical | 6–7 | [ |
| 1.20 |
| Antibacterial | - | Spherical | 25 | [ |
| 1.21 |
| Antibacterial | - | Rod, triangular, hexagonal | 3–77 | [ |
| 1.22 |
| Antibacterial | - | Spherical | 20–25 | [ |
| 1.23 |
| Antibacterial | - | Spherical | 13 | [ |
| 1.24 |
| Antibacterial | - | Spherical | 20 | [ |
| 1.25 |
| Antibacterial | - | Polydispersed | 35 | [ |
| 1.26 |
| Cytotoxicity | CHO-K1 cells | Spherical, triangular | 50 | [ |
| 1.27 |
| Antibacterial | - | Spherical | 30–50 | [ |
| 1.28 |
| Antibacterial | - | Spherical | 8–37 | [ |
| 1.29 |
| Antibacterial | - | Spherical | 80 | [ |
| 1.30 |
| Antibacterial | - | Square | 50 | [ |
| 1.31 |
| Antibacterial | - | Hexagonal | 78 | [ |
| 1.32 |
| Antibacterial, Leshmenia | - | Hexagonal | 30 | [ |
| 1.33 |
| Antibacterial | - | Diverse | 300 | [ |
| 1.34 |
| Antibacterial | - | Spherical | 50–80 | [ |
| 1.35 |
| Antibacterial | - | Spherical | 3–37 | [ |
| 1.36 |
| Antibacterial | - | Spherical | 5.20 | [ |
| 1.37 |
| Antibacterial | - | Granular | 20–200 | [ |
| 1.38 |
| Antibacterial | - | Spherical | 16–28 | [ |
| 1.39 |
| Antimicrobial | - | Spherical | 15 | [ |
| 1.40 |
| Antibacterial | - | Spherical | 10–50 | [ |
| 1.41 |
| Antibacterial | - | Spherical | 50 | [ |
| 1.42 |
| Antibacterial | - | Polydispersed | 22–35 | [ |
| 1.43 |
| Antibacterial | - | Diverse | 14 | [ |
| 1.44 |
| Antibacterial | - | Pseudospheric | 1–24 | [ |
| 1.45 |
| Antibacterial | - | Spherical, hexagonal, cuboidal | 38–80 | [ |
| 1.46 |
| Antibacterial | - | Spherical | 5–15 | [ |
| 1.47 |
| Antibacterial | - | Spherical | 20–40 | [ |
| 2 | Nanoparticles with Anticancer activity | |||||
| 2.1 |
| Anticancer, catalyst | HeLa | Spherical | 13 | [ |
| 2.2 |
| Anticancer | HeLa, RKO and A549 | Spherical | 5–40 | [ |
| 2.3 |
| Anticancer | HeLa (Cervical) | Spherical, hexagonal, triangular | 9 | [ |
| 2.4 |
| Anticancer | HeLa (Cervical) | Spherical | 23 | [ |
| 2.5 |
| Anticancer | Bladder (T24) and prostate (PC-3) | Rods, triangular, pentagonal, hexagonal | 8–15 | [ |
| 2.6 |
| Anticancer | HL-60 | Cubic | 27 | [ |
| 2.7 |
| Anticancer | A498(renal carcinoma) | Spherical | 200 | [ |
| 2.8 |
| Anticancer | HCT-116 (colon cancer) | Spherical | 20–48 | [ |
| 2.9 |
| Antiproliferative effect | (Breast) MCF-7, (colon) | Triangular, hexagonal | 37–50 | [ |
| 2.10 |
| Anticancer | HeLa | Diverse | 70–90 | [ |
| 2.11 |
| Cytotoxicity | B16/F10 (melanoma) | Diverse | 19–56 | [ |
| 2.12 |
| Anticancer | K562 and HeLa | Spherical | 11 | [ |
| 2.13 |
| Anticancer | Cervical cancer (HeLa) | Spherical | 20–25 | [ |
| 2.14 |
| Cytoxicity and genotoxicity | CHO-K1 cells | Spherical, triangular | 50 | [ |
| 2.15 |
| Anticancer | (Lung cancer) A549 | Spherical | 30–50 | [ |
| 2.16 |
| Anticancer | Cervical cancer (HeLa) | Spherical | 8–37 | [ |
| 2.17 |
| Anticancer | (Lung cancer) A459 | Spherical | 80 | [ |
| 2.18 |
| Anticancer | (Lung cancer) A459 | Diverse | 300 | [ |
| 2.19 |
| Anticancer | (Lung cancer) A459 | Spherical | 50 | [ |
| 2.20 |
| Anticancer | (Lung adenocarcinoma) (A549) | Spherical | 10–40 | [ |
| 2.21 |
| Cytotoxicity | African green monkey kidney normal cells (CV-1) and fetal lung fibroblast cells (WI-38) | Round, triangular, irregular | 19–45 | [ |
| 2.22 |
| Anticancer | MCF-7 (breast cancer) | Spherical | 2–10 | [ |
| 2.23 |
| Anticancer | (Human cervical) HeLA | Cubic | 33 | [ |
| 2.24 |
| Cytotoxicity and catalytic activities | H1299 and MCF-7 | Spherical | 3–37 | [ |
| 2.25 |
| Anticancer | AMG-13 (breast cancer) | Spherical | 14–50 | [ |
| 2.26 |
| Anticancer | HeLa | Spherical | 5–20 | [ |
| 2.27 |
| Anticancer | (cervical), HeLa, Hep2 | Spherical | 3–40 | [ |
| 2.28 |
| Anticancer | Liver cancer (HepG2) and lung cancer (A549) | Spherical | 8–10 | [ |
| 2.29 |
| Anticancer | Pancreatic (PANC-1) | Spherical | 154 | [ |
| 2.30 |
| Anticancer | Human breast cancer cell line (MCF-7) | Spherical | 4–10 | [ |
| 2.31 |
| Anticancer | Human cervical carcinoma (HeLa) | Spherical | 35 | [ |
| 2.32 |
| Anticancer | MCF-7 (breast cancer) | Cubic, spherical | 20–50 | [ |
| 2.33 |
| Anticancer | Breast cells (MCF-7), cervical cells (HeLa) and ovarian cells (Caov-4) | Dispersed | 20 | [ |
| 2.34 |
| Anticancer | HCT 15 (colon cancer) | Spherical, cubic | 10–50 | [ |
| 2.35 |
| Cytotoxicity | HeLa and HEK293 | Prism, cubic, octahedron, tetrahedron, dodecahedron, triangular | 15–55 | [ |
| 3 | Nanoparticles with Antifungal activity | |||||
| 3.1 |
| Antifungal | Crystalline | 62 | [ | |
| 3.2 |
| Larvicidal activity against Aedes | Spherical, triangular, hexagonal | 50–100 | [ | |
| 3.3 |
| Antifungal | Rods, triangular, pentagonal, hexagonal | 8–15 | [ | |
| 3.4 |
| Detections of aflatoxins | [ | |||
| 3.5 |
| Antifungal | Triangular, spherical | 40–200 | [ | |
| 3.6 |
| Antifungal | Spherical | 10–50 | [ | |
| 3.7 |
| Antifungal | Spherical | 20–25 | [ | |
| 3.8 |
| Antifungal | Polydispersed | 35 | [ | |
| 3.9 |
| Antifungal | Spherical | 50–80 | [ | |
| 3.10 |
| Antifungal | Spherical | 5–20 | [ | |
| 3.11 |
| Antifungal | Granular | 20–200 | [ | |
| 3.12 |
| Antifungal | Spherical | 10–50 | [ | |
| 3.13 |
| Antifungal | Spherical, hexagonal, cuboidal | 38–80 | [ | |
| 4 | Nanoparticles with Antioxidant activity/antidiabetic activity | |||||
| 4.1 |
| Catalyst, antioxidant | HeLa | Spherical | 13.7 | [ |
| 4.2 |
| Antioxidant | Spherical, triangular, hexagonal | 10 | [ | |
| 4.3 |
| Antioxidant | HL-60 | Cubic | 27 | [ |
| 4.4 |
| Antioxidant | Spherical | 20 | [ | |
| 4.5 |
| Antidiabetic and anti-inflammatory | (Lung cancer) A549 | Spherical | 30–50 | [ |
| 4.6 |
| Antioxidant | MCF-7 (breast cancer) | Spherical | 2–10 | [ |
| 4.7 |
| Antioxidant, catalytic activities | H1299 and MCF-7 | Spherical | 3–37 | [ |